How big is LivaNova Plc?

As of Jun 18, LivaNova Plc has a market capitalization of 2,440.86 million, with net sales of 1,275.35 million and a net profit of -222.14 million over the latest four quarters.

Market Cap: As of Jun 18, LivaNova Plc has a market capitalization of 2,440.86 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, LivaNova Plc reported net sales of 1,275.35 million and a net profit of -222.14 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,320.26 million and total assets of 2,506.39 million.

What does LivaNova Plc do?

LivaNova Plc is a small-cap medical device company focused on therapeutic solutions in the Pharmaceuticals & Biotechnology industry, with recent net sales of $317 million and a net loss of $327 million. The company has a market cap of $2.44 billion and does not currently pay dividends.

Overview: <BR>LivaNova Plc is a medical device company focused on the development and delivery of therapeutic solutions within the Pharmaceuticals & Biotechnology industry, categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 317 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -327 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,440.86 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.10 <BR>Return on Equity: -25.56% <BR>Price to Book: 2.36<BR><BR>Contact Details: <BR>Address: 20 Eastbourne Terrace, LONDON None: W2 6LG <BR>Tel: 44 20 33250662 <BR>Website: http://www.livanova.com/home.action

Should I buy, sell or hold LivaNova Plc?

Who are in the management team of LivaNova Plc?

As of March 2022, the management team of LivaNova Plc includes Mr. Daniel Moore (Independent Chairman), Mr. Damien McDonald (CEO), and several Independent Directors: Mr. Todd Schermerhorn, Mr. Francesco Bianchi, Mr. William Kozy, Mr. Alfred Novak, and Dr. Sharon O'Kane. They oversee the company's strategic direction and governance.

As of March 2022, the management team of LivaNova Plc includes the following individuals:<BR><BR>- Mr. Daniel Moore, who serves as the Independent Chairman of the Board.<BR>- Mr. Damien McDonald, who is the Chief Executive Officer and a Director.<BR>- Mr. Todd Schermerhorn, who is a Director.<BR>- Mr. Francesco Bianchi, who is an Independent Director.<BR>- Mr. William Kozy, who is also an Independent Director.<BR>- Mr. Alfred Novak, who holds the position of Independent Director.<BR>- Dr. Sharon O'Kane, who is an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and governance of the company.

Is LivaNova Plc overvalued or undervalued?

As of May 7, 2025, LivaNova Plc is considered overvalued and risky due to its negative P/E ratio, poor returns on capital, and underperformance compared to peers and the S&P 500.

As of 7 May 2025, LivaNova Plc's valuation grade has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, particularly given its negative P/E ratio and poor returns on capital, with a Price to Book Value of 2.45 and an EV to Sales ratio of 1.90. In comparison, peers such as Globus Medical, Inc. have a much more favorable P/E ratio of 18.37, while Sanmina Corp. boasts a significantly higher P/E of 39.80, highlighting LivaNova's relative weakness in valuation metrics.<BR><BR>Additionally, LivaNova's recent stock performance has lagged behind the S&P 500, with a YTD return of 20.73% compared to the index's 12.22%, but over the longer term, its 5-year return of 25.05% still falls short of the S&P 500's 96.61%. This underperformance, combined with the company's negative financial ratios, reinforces the conclusion that LivaNova is overvalued in its current state.

Is LivaNova Plc technically bullish or bearish?

As of August 13, 2025, LivaNova Plc's technical trend has shifted to bullish, supported by positive indicators like a bullish MACD and moving averages, despite underperforming the S&P 500 over the long term but outperforming year-to-date.

As of 13 August 2025, the technical trend for LivaNova Plc has changed from mildly bullish to bullish. Key indicators supporting this bullish stance include a bullish MACD on the weekly timeframe, bullish moving averages on the daily timeframe, and a bullish KST on the weekly. While the monthly MACD is mildly bullish, the overall sentiment remains positive. The stock has underperformed the S&P 500 over the 1-year, 3-year, and 5-year periods, but has outperformed in the year-to-date comparison.